Background-Female sex was reported to be associated with lower risk for midterm restenosis and repeat revascularization after bare-metal stent implantation. However, the influence of sex on very long-term outcomes after bare-metal stent implantation has not been yet reported. Methods and Results-Among the 9877 patients in the multicenter Coronary Revascularization Demonstrating Outcome study in Kyoto (CREDO-Kyoto) registry cohort-1, bare-metal stent implantation was performed in 5313 patients (men, n=3742 and women, n=1571). Follow-up was completed in 4515 patients (85.0%) at 10 years (duration, 10.3±3.1 [0.0-14.1] years). The cumulative incidence of target-lesion revascularization (TLR) was 27% at 1 year and 34% at 10 years (0.8%/y beyond 1 year). Non-target-lesion revascularization (non-TLR) was the dominant coronary revascularization beyond 1 year (13% at 1 year and 31% at 10 years [2.0%/y beyond 1 year]). Cumulative incidence of stent thrombosis was low (1.2% at 1 year and 1.9% at 10 years). Women were older and had greater prevalence of cardiovascular risk factors than men. The cumulative 10-year incidences of and adjusted risk for TLR were significantly higher in men than in women (36% versus 30%, P<0.001; adjusted hazard ratio, 1.29; 95% confidence interval, 1.15-1.46; P<0.001). The higher risk of men relative to women for TLR was consistent regardless of age (<75 years and ≥75 years). Men in comparison with women were also associated with significantly higher adjusted risks for all-cause death, myocardial infarction, stroke, coronary artery bypass grafting, TLR, and non-TLR. Conclusions-TLR and stent thrombosis continued to occur without attenuation up to 10 years after bare-metal stent implantation. Men in comparison with women were associated with higher adjusted 10-year risks for all-cause death, myocardial infarction, stroke, coronary artery bypass grafting, TLR, and non-TLR. 
B
are-metal stents (BMS) have been widely used and reduced the incidence of early restenosis and targetlesion revascularization (TLR) in comparison with balloon angioplasty.
1,2 However, several single-center studies reporting very long-term (≥10 years) outcomes after coronary BMS implantation demonstrated that TLR continued to occur throughout the follow-up duration. [3] [4] [5] [6] First-generation drugeluting stents (DES) succeeded in further reducing the rate of early TLR, 7, 8 but were associated with continued occurrence of late TLR and very late stent thrombosis (ST), which might have been attenuated with newer-generation DES using biocompatible or biodegradable polymer. [9] [10] [11] Currently, a fully bioresorbable drug-eluting vascular scaffold (BVS) is under clinical evaluation with expectations for better healing responses of the vessel wall and reduction of late adverse events related to the treatment site by eliminating permanent metallic implants. 12, 13 Long-term outcomes of BMS would be an important benchmark for evaluating newer-generation DES and BVS. However, to date, there has been no large-scale multicenter real-world registry reporting very long-term outcomes (≥10 years) after BMS implantation.
Therefore, we conducted an extended (10-14 years) follow-up of patients undergoing BMS implantation from a large Japanese multicenter coronary revascularization registry. In the current report, we focused on the influence of sex on very long-term outcomes after BMS implantation, because female sex was reported to be associated with lower adjusted risk for midterm restenosis and repeat revascularization after BMS implantation.
14,15

Methods
Patient Population
The Coronary Revascularization Demonstrating Outcome study in Kyoto (CREDO-Kyoto) registry cohort-1 is a multicenter registry enrolling consecutive patients undergoing first coronary revascularization either by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) in the BMS era (January 2000 and December 2002), excluding those patients with acute myocardial infarction within a week before the index procedure. The design, patient enrollment, and 3-year outcomes of the CREDO-Kyoto registry cohort-1 have been described previously. 16 In the current study, we extended the follow-up to at least 10 years to investigate the very long-term outcomes after BMS implantation. Among 9877 patients (6878 patients in the PCI cohort and 2999 patients in the CABG cohort), a total of 469 patients were excluded from the extended very long-term follow-up study; 4 patients included in the original cohort were revealed to have had an acute myocardial infarction within a week before the index procedure; 5 centers (415 patients) did not participate in the extended study; and 51 patients refused to participate in the study when contacted for follow-up. After further excluding 2930 patients in the CABG cohort and 1164 patients who underwent balloon angioplasty only, a total of 5313 consecutive patients who underwent BMS implantation from 26 Japanese centers (online-only Data Supplement Appendix A) made up the current very long-term follow-up study population. There were 3742 male patients (70.4%) and 1571 female patients (29.6%) in the current study population (online-only Data Supplement Figure I ). The relevant review boards in all participating centers approved the follow-up research protocol. Because of the retrospective enrollment, written informed consent was waived for patients; however, patients who refused to participate in the study when contacted for follow-up were excluded. This strategy is concordant with the guidelines of the Japanese Ministry of Health, Labor and Welfare.
Data Collection and Definitions
Demographic, angiographic, and procedural data were collected from hospital charts or databases in each center according to the prespecified definitions. Follow-up data were obtained from hospital charts or by contacting patients or referring physicians. Data were collected by the independent clinical research coordinators in the clinical research organization (Research Institute for Production Development, Kyoto, Japan [online-only Data Supplement Appendix B]). Baseline clinical characteristics, such as myocardial infarction (MI), heart failure, diabetes mellitus, hypertension, current smoking status, atrial fibrillation, chronic obstructive pulmonary disease, and malignancy were regarded as present when these diagnoses were recorded in the hospital charts. Stroke at baseline included asymptomatic stroke detected by noninvasive imaging modalities. Peripheral vascular disease was regarded to be present when carotid, aortic, or other peripheral vascular diseases were being treated or scheduled for surgical or endovascular interventions. Elderly patients were defined as those ≥75 years of age. Left ventricular ejection fraction was measured either by contrast left ventriculography or echocardiography. Patients with a left ventricular ejection fraction ≤40% were regarded as having left ventricular dysfunction. Chronic kidney disease was regarded as present when creatinine clearance estimated by the Cockcroft-Gault formula was <30 mL/min. Anemia was defined as blood hemoglobin level <10 g/dL.
Clinical Outcomes
The primary outcome measure in the current analysis was TLR. Other outcome measures included death, cardiac death, noncardiac death, MI, ST, stroke, non-target-lesion revascularization (non-TLR), and any coronary revascularization. TLR was defined as PCI because of restenosis or thrombosis of the target lesion that included the proximal and distal edge segments, and the ostium of the side branches, as well, or any CABG. ST was defined according to the Academic Research Consortium definition. 17 Death was regarded as cardiac in origin unless obvious noncardiac causes could be identified. Any death during the index hospitalization was regarded as cardiac death. MI was adjudicated according to the definition in the Arterial Revascularization Therapy Study. 18 Within 1 week of the index procedure, only Q-wave MI was adjudicated as MI. Stroke was defined as symptomatic stroke. An independent clinical events committee adjudicated death, MI, ST, stroke, TLR, and non-TLR (online-only Data Supplement Appendix C).
Statistical Analysis
Categorical variables were compared with the χ 2 test. Continuous variables were expressed as mean value±standard deviation or median and 25th to 75th percentiles. Continuous variables were compared by using the Student t test. Cumulative incidences were estimated by the Kaplan-Meier method and compared by using the log-rank test. Cumulative incidence estimators of events accounting for competing risk were also calculated and presented. 19 To evaluate the events within 1 year and beyond 1 year, we conducted a landmark analysis at 1 year. 20 Those patients with the events before 1 year were excluded in the landmark analysis. To identify independent risk factors for TLR after BMS implantation, we used Cox proportional hazards models. We chose 35 clinically relevant factors as independent variables as listed in Table 1 . The continuous variables were dichotomized by clinically meaningful reference values. Center was included in the models as the stratification variable. We evaluated the adjusted risk of men relative to women for all the outcome measures by using Cox proportional hazards models with 34 clinically relevant factors as risk-adjusting variables. The risk of men relative to women was expressed as hazard ratio with 95% confidence interval. We constructed the model in which age and BMI were included as continuous variables in a sensitivity analysis and found no difference (data not shown). We also conducted a subgroup analysis stratified by age (<75 years and ≥75 years) with a formal interaction test between the age group and the risk of men relative to women.
Statistical analyses were performed with the use of R version 3.1.3 (R Foundation for Statistical Computing, Vienna, Austria) and SAS 9.4 (SAS Institute, Cary, NC). All the statistical analyses were 2-tailed. P values <0.05 were considered statistically significant.
Results
Baseline Characteristics
The current study population included a significant proportion of patients with advanced age, diabetes mellitus, heart failure, renal failure, peripheral vascular disease, and previous stroke. The study population also included those patients with complex coronary anatomy as reflected by the high prevalence of multivessel PCI, long total stent length, and target of chronic total occlusion (Table 1) . Regarding the differences in the baseline clinical and procedural characteristics between sexes, women were older (online-only Data Supplement Figure II ) and had greater prevalence of cardiovascular risk factors such as hypertension, insulin-treated diabetes mellitus, renal failure, and anemia, whereas men more often had current smoking habits and chronic obstructive pulmonary disease. Women more frequently had a history of heart failure and concomitant severe mitral regurgitation, whereas men were more likely to have previous histories of MI, stroke, and peripheral vascular disease. In terms of lesion and procedural characteristics, women received significantly smaller stents, but the number of target lesions and stents used were similar between men and women. Women more often underwent PCI for the target of proximal left anterior descending artery and less frequently underwent PCI for chronic total occlusion. With regard to medication at hospital discharge, statins were more frequently prescribed in women than in men (Table 1) .
Clinical Outcomes in the Entire Cohort
Mean follow-up duration for the survivors were 10.3±3.1 years (median, 11.3 years; 25th-75th percentiles, 10.3-12.2 years; range, 0.0-14.1 years). Late clinical follow-up information was obtained in 4901 (92.2%) patients at 5 years and 4515 (85.0%) patients at 10 years. The cumulative incidence of TLR (the primary outcome measure) was 27% at 1 year, 31% at 5 years, and 34% at 10 years (Table 2) . Beyond 1 year after BMS implantation, TLR occurred constantly at the rate of 0.8%/y ( Figure 1 ). Cumulative incidences of TLR and non-TLR were quite comparable at 10 years. However, TLR was the dominant coronary revascularization within 1 year after BMS implantation, whereas non-TLR was the dominant coronary revascularization beyond 1 year (2.0%/y) ( Figure 1 ). The cumulative incidences of death, cardiac death, noncardiac death, MI, and stroke at 10 years were 28%, 12%, 18%, 7.8%, and 11%, respectively. The cumulative incidence of ST was low (1.9% at 10 years), and more than half of ST events occurred within 1 year (1.2% at 1 year). There was a signal suggesting slight increase in the rate of ST beyond 5 years (1-5 years, 0.03%/y; and beyond 5 years, 0.12%/y) ( Table 2 and Figure 1 ).
Risk Factors for TLR
Independent risk factors for TLR during the entire follow-up period included male sex, diabetes mellitus, chronic obstructive pulmonary disease, minimal stent diameter <3.0 mm, total stent length >28 mm, target of proximal left anterior descending artery, target of chronic total occlusion, and use of the rotablator, whereas negative risk factors included current smoking, previous MI, and renal failure (estimated glomerular filtration rate <30 mL·min -1 ·1.73 m -2 ) not on dialysis (Table 3 and online-only Data Supplement Table I ). The risk factors for early TLR within 1 year and late TLR beyond 1 year were mostly similar; however, the target of proximal left anterior descending artery was a risk factor for early TLR, but was a negative risk factor for late TLR (Table 3) .
Clinical Outcomes: Men Versus Women
Follow-up duration for the survivors was significantly longer in men than in women (mean, 10 The cumulative 10-year incidences of TLR and non-TLR were significantly higher in men than in women (Table 2 and Figure 2 ). After adjusting baseline characteristics, the excess risk of men relative to women for both TLR and non-TLR remained significant. The higher risk of men relative to women was similarly seen for early TLR within 1 year and late TLR beyond 1 year (Table 4 ). The higher risk of men relative to women for TLR was consistent regardless of age (<75 years and ≥75 years). There was no interaction between the age group and the risk of men relative to women for TLR ( Figure 3) . Within 1 year after the index procedure, 2783 (74.4%) of the men and 1135 (72.3%) of the women underwent follow-up angiography either because of symptoms or for the scheduled follow-up (P=0.11).
The cumulative 10-year incidence of all-cause death was similar between men and women (Table 2 and Figure 2 ). However, after adjusting baseline characteristics, the higher risk of men relative to women for all-cause death was significant, which was mainly driven by the higher risk for noncardiac death ( was significantly higher in women than in men (Table 2) , whereas the adjusted risk of men relative to women was not significant ( Table 4 ). The higher adjusted risks of men relative to women for MI and stroke were also significant, whereas the influence of sex was neutral for ST (Table 4 ).
Discussion
The current study reports the longest follow-up outcomes after BMS implantation from a large-scale multicenter real-world registry. The main findings of the present study were as follows:
(1) TLR and ST continued to occur without attenuation up to 10 years after BMS implantation; (2) men in comparison with women were associated with higher adjusted 10-year risks for all-cause death, MI, stroke, CABG, TLR, and non-TLR. We previously reported the very late outcomes after PalmazSchatz stent implantation in 405 patients from a single-center observational study demonstrating late progressive angiographic restenosis and corresponding increase in the incidence of TLR from 18.5% at 4 years to 36.0% at 15 years. 5 From a large single-center study of 4503 patients, Doyle et al 3 also reported that TLR and ST after BMS implantation continued to occur up to 10 years, and the MI caused by restenosis and ST of BMS were both associated with mortality. The current multicenter registry with the extended follow-up confirmed those single-center observations that late adverse events such as TLR and ST after BMS implantation continued to occur without attenuation. In our previous single-center study of 405 patients, there was a signal suggesting accelerated occurrence of TLR beyond 4 to 5 years coinciding with the timing of neoatherosclerosis formation inside the stent struts of BMS reported from the human pathological studies. 5, 21, 22 In the current study, we could not confirm the acceleration of clinical restenosis beyond 4 to 5 years; the annual rate of TLR seemed constant beyond 1 year up to 10 to 14 years. One of the reasons for the discrepancy might be related to the possible differences in the threshold for the choice of angiographic follow-up and the decision for repeat revascularization between the single-center and multicenter studies. However, we saw a signal suggesting a slight increase in the rate of ST beyond 5 years (1-5 years, 0.03%/y; and beyond 5 years, 0.12%/y), although the observation on this low-frequency event was underpowered and should be confirmed by other studies.
Although DES reduced the incidence of early TLR in comparison with BMS, late catch-up phenomena in terms of TLR and ST emerged as clinical issues. 23 Endothelial function was more frequently impaired in lesions with DES implantation than in those with BMS. 24, 25 Endothelial dysfunction after DES implantation might accelerate the atherosclerotic changes in the stented lesion in concert with inflammatory reactions to metallic prostheses, leading to increased risk for late adverse events. BVS have been introduced aiming at preventing late adverse events 12, 13 and restoration of endothelial function. 26 Restoration of endothelial function after complete absorption of BVS might ameliorate the progression of neoatherosclerosis in comparison with metallic stents. Very longterm outcomes of BMS reported in the current multicenter study could be a benchmark for the BVS to overcome.
In this study, women generally had higher clinical risk profiles than men. Women were older and had a higher prevalence of cardiovascular risk factors, with the exception of smoking habits, at the time of their first PCI. These observations were in line with previous studies comparing women with men in terms of the clinical outcomes after PCI in patients with stable coronary artery disease. 14, 27, 28 Higher crude cardiac mortality in women, which was no longer significant after adjusting for known confounders, was attributed to those baseline differences. However, women in comparison with men were associated with significantly lower risk for all-cause death, which was mainly driven by the lower risk for noncardiac death. It is well known that women in comparison with men present less frequently with severe coronary artery disease, which might have an impact particularly on very long-term outcomes. 29 In the current analysis, the prevalence of chronic total occlusion was significantly higher in men than in women. However, there were no other differences between men and women in those factors related to the severity of coronary artery disease such as multivessel PCI, number of target lesions, number of stents implanted, total stent length, target of unprotected left main coronary artery, and use of rotablator. The selection of patients who underwent BMS implantation might be one of the reasons why the severity of coronary artery disease was not so different between men and women in the current study. We had previously reported the sex-related differences in the midterm revascularization outcome from the entire CREDOKyoto registry cohort-1 including patients who underwent either PCI or CABG. 14 We found that women in comparison with men were associated with a lower incidence of repeated revascularization at 3 years. Mehilli et al 15 also reported that women had a lower risk of restenosis after BMS implantation despite the preponderance of 2 major risk factors for restenosis, such as diabetes mellitus and small vessel size. In the current study, women in comparison with men were associated with significantly lower very long-term risk for both TLR and non-TLR. Those differences in the risk for TLR and non-TLR might in part derive from the lower prevalence of follow-up coronary angiography in women than in men; however, that finding could not explain the late progressive divergence in the incidences of late TLR and non-TLR.
Because of the protective effect of estrogen until their menopause, women tend to be 10 years older than men when presenting with coronary artery disease. [30] [31] [32] In the substudy of Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT), men in the same age group had a greater frequency of fibroatheromas and nonculprit lesions with larger plaque volume, despite the higher Framingham risk score in women than in men. Plaque ruptures were also observed more frequently in younger men than in women. The higher prevalence of high-risk atherosclerotic changes in the nontarget coronary arteries in men in comparison with women might in part explain their higher risk for non-TLR observed in the current study.
In addition to the greater atheroma burden, men also had more diffuse epicardial endothelial dysfunction than women, 33 which could be a precursor of late development of atherosclerosis and a risk for late cardiovascular events. [34] [35] [36] Although the difference of sex hormones would be negligible in the current study because of the elderly study population, there remained a possible sex difference in the progression of atherosclerosis because of the difference in endothelial function. The neoatherosclerosis initiated by the inflammatory reactions to the foreign metallic stents might be one of the mechanisms for late BMS restenosis leading to TLR beyond 4 to 6 years. 21, 22 More aggressive atherosclerotic progression in men than in women would be associated with higher longterm risks for not only non-TLR, but also TLR.
Study Limitations
The present study has several important limitations. First, symptomatic status at the time of TLR or scheduled followup angiography was not assessed in the current study. Almost three-fourths of the patients underwent follow-up angiography within 1 year, which was a common clinical practice among participating centers, and might have increased the incidence of early TLR with so-called oculostenotic reflex. However, those effects would be less prominent for the late TLR beyond 1 year. Second, because we did not assess the angiograms at the time of repeat coronary revascularization, ascertainment of TLR and ST might be inaccurate in some cases. Third, the factors affecting disease progression and even late mortality such as medication compliance and smoking status were not ascertained despite the long follow-up duration of this study. Forth, because we did not collect data on follow-up stress testing, symptoms, or follow-up angiography in the longer-term follow-up, we could not deny the presence of a sex-related selection bias for angiographic follow-up and decision for revascularization. Fifth, the follow-up rate was higher in men than in women. Given that 10-year clinical information was obtained by reviewing hospital charts in 51.2% of men and 46.5% of women (online-only Data Supplement Figure III ), men might be followed up more often by the physicians in the original PCI center. Finally, despite enrollment of a large number of patients in this multicenter registry, the current study population still did not have adequate statistical power to compare the incidence of a rare event such as ST between men and women.
Conclusions
TLR and ST continued to occur without attenuation up to 10 years after BMS implantation. Men in comparison with women were associated with higher adjusted 10-year risks for all-cause death, MI, stroke, TLR, and non-TLR. 
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